Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference

Core Insights - Anavex Life Sciences Corp. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, highlighting its focus on innovative treatments for CNS disorders [1][3] - The company is dedicated to developing therapeutics for Alzheimer's disease, Parkinson's disease, schizophrenia, and other neurodegenerative and neurodevelopmental disorders [4] Company Overview - Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker AVXL [1][4] - The company's lead drug candidate, ANAVEX®2-73 (blarcamesine), has completed multiple clinical trials for Alzheimer's disease and is also being studied for Parkinson's disease dementia and Rett syndrome [4] - ANAVEX®2-73 is designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, showing potential to halt or reverse Alzheimer's disease progression [4] - The company is also developing ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, demonstrating disease-modifying activity against Alzheimer's disease in preclinical studies [4]